NCT04142424 - A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 28, 2019

Primary Completion Date

November 12, 2021

Study Completion Date

November 12, 2021

Conditions

Metabolic DisordersNon-alcoholic Steatohepatitis

Interventions

DRUG

AZD2693

Subjects will receive SC injection of AZD2693 as per the arms they are randomized.

DRUG

Placebo

Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.

Trial Locations (1)

Research Site, Glendale